The availability of compounded GLP-1 drugs shifted after the FDA changed their regulations in April 2025. Here’s what to know.

If approved, it would be the first major new drug treatment for Parkinson’s in half a century. Richard Mailman, a University ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

This article is the latest in the Health Affairs Forefront featured topic, “Health Policy at a Crossroads,” produced with the support of the Commonwealth Fund and the Robert Wood Johnson Foundation.

This shift could improve care coordination and create opportunities for cost savings through enhanced formulary flexibility ...